APA (7th ed.) Citation

H, H. (2026). Editorial Comment to "Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab". International journal of urology : official journal of the Japanese Urological Association, 33(10), e70658. https://doi.org/10.1111/iju.70658

Chicago Style (17th ed.) Citation

H, Hirata. "Editorial Comment to "Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab"." International Journal of Urology : Official Journal of the Japanese Urological Association 33, no. 10 (2026): e70658. https://doi.org/10.1111/iju.70658.

MLA (9th ed.) Citation

H, Hirata. "Editorial Comment to "Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab"." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 33, no. 10, 2026, p. e70658, https://doi.org/10.1111/iju.70658.